Learn more about the LUCINDA Trial

Contact: Meg Hackbarth Clinical Research Coordinator

608-263-1909 mmhackbarth@clinicaltrials.wisc.edu


adrc.wisc.edu/lucinda

STUDY LEADERSHIP

Craig Atwood, PhD University of Wisconsin–Madison Madison, WI

> **Tracy Butler, MD** Weill Cornell Medicine New York, NY

James Galvin, MD University of Miami Miami, FL





LUCINDA

LeUprolide + Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's









About the study

LUCINDA is a clinical research trial to determine whether leuprolide (Eligard, an injectable medication) can slow or prevent decline in thinking abilities and functioning in women with mild cognitive impairment or Alzheimer's disease who are also taking a cholinesterase inhibitor medication such as donepezil (Aricept).

What does the study involve?

If you are interested, a research coordinator will give you detailed information about the study. You will be asked to sign an informed consent form. There will be approximately eight study visits spread out over one year. Study procedures include tests of thinking abilities, blood tests, two MRI scans and one PET scan to measure amyloid in the brain. There will be injection of study drug (leuprolide or placebo) four times over one year.

What is leuprolide normally used for?

Leuprolide is approved by the FDA for treatment of prostate cancer in men, endometriosis in women, and early puberty in children. It is also commonly used in women preparing for in vitro fertilization. LUCINDA aims to *repurpose* leuprolide for Alzheimer's disease.

Key eligibility

- Women over age 60
- Diagnosed with mild cognitive impairment or Alzheimer's disease
- Taking a cholinesterase inhibitor such as donepezil (Aricept)
- Participants must have a study partner (friend, family member or caregiver) who can accompany them to all study visits
- Detailed eligibility will be reviewed with the study team

There is no cost to be in this study. You will be compensated for your time and effort.